EN DE

Elevance Health, Inc (ELV) Fair Value & Analysis

Healthcare · US · Market cap $80.9B

EH Elevance Health, Inc logo Elevance Health, Inc ELV · US
Price$391.40
Fair Value$431.40
Upside+10.2%
Quality65/100
Watch Elevance Health, Inc for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 2.5% net margin
Moderate debt · generates free cash flow
1.76% dividend yield
Ranks above peers (11/14)
Moderate moat 46/100
Evidence: High Range $196.19 – $669.86 Share as image

Fair value as of: Jul 17, 2026

From 26 valuation models · updated 21 days ago

Share price −6.6% over the past month.

A solid business, screening 10% undervalued on our models.

What matters now

  • The model range is unusually wide ($196.19 to $669.86). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Our model range runs from $196.19 (bear) to $669.86 (bull), base $431.40. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 65/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$542.16 $269.01 Fair Value $431.40 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range $269.01 – $542.16 · fair‑value band $196.19 – $669.86 · the $391.40 price screens below the $431.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Elevance Health, Inc (ELV) currently trades at $391.40, while our model-based Fair Value estimate is $431.40, implying the stock looks roughly 10.2% undervalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Elevance Health, Inc generated revenue of $200B at a net margin of 2.6%. Revenue grew 2.6% year over year. It earns a return on equity of 12.1%. Net debt stands at $23.7B. Fundamentals as of Jul 17, 2026

Our scenario range runs from $196.19 (bear case) to $669.86 (bull case); at $391.40, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 10%, ELV screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF $82.60 $205.81 $407.84 80
Residual Income $191.80 $235.61 $540.75 76
Rev-Margin DCF $183.95 $407.96 $685.77 74
All 26 models by family
DCF Models
FCF DCF $82.39 $212.31 $428.57 38
Owner Earnings $248.46 $497.81 $912.90 31
5Y Revenue Exit $183.95 $415.22 $727.45 39
5Y EBITDA Exit $226.38 $499.86 $838.23 41
5Y P/E Exit $200.38 $448.00 $725.29 38
10Y Revenue Exit $136.02 $342.65 $653.72 36
10Y EBITDA Exit $174.97 $403.54 $743.58 37
10Y P/E Exit $157.97 $366.23 $651.97 35
Earnings-Based
Graham-Dodd $177.53 $730.60 $995.27 54
Lynch FV $183.85 $262.65 $341.44 50
PEG = 1.0 $183.85 $262.65 $341.44 46
EPV $211.93 $263.62 $308.86 59
Dividend Discount
Gordon GGM $64.73 $134.60 $213.52 70
DDM Multi-Stage $64.73 $113.50 $141.26 61
Multiples
P/E Multiple $391.62 $522.16 $652.70 63
P/S Multiple $332.88 $443.83 $554.79 58
P/B Multiple $332.88 $443.83 $554.79 55
EV/EBIT $406.72 $575.05 $743.37 53
EV/EBITDA $335.96 $480.70 $625.43 54
EV/Revenue $242.14 $388.02 $533.90 43
Asset-Based
NCAV (Graham) $101.17 $135.57 $202.34 50
Growth DCF
Growth DCF $82.60 $205.81 $407.84 80
Rev-Margin DCF $183.95 $407.96 $685.77 74
Economic Profit
Residual Income $191.80 $235.61 $540.75 76
ROIC Compounder $216.29 $319.10 $462.24 72
Growth Earnings
Growth-Adj P/E $307.99 $439.99 $571.99 68

Widest divergence: Multiples ($443.83) versus Dividend Discount ($113.50). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) $201B
Revenue growth (YoY) +1.4%
Net margin 2.5%
Return on equity 11.1%
Free cash flow $3.2B FY2025
P/E ratio 16.5
More key figures
Operating margin 4.6%
EPS (TTM) $22.59
Dividend yield 1.8%
EPS growth (YoY) -13.1%
Net debt $23.7B FY2025

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 65/100

Of which business quality 60 · Market factors (momentum, volatility) 71

Profitability 58
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 56
Balance sheet, leverage, solvency risk
Investment 80
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 68
Price trend over the last 3–12 months (market factor)
52W Momentum 79
Distance to the 52-week high (market factor)
Net Issuance 100
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

Full company description

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Elevance Health, Inc reported revenue of $199B in FY2025 versus $139B in FY2021, a compound +9.5%/yr. Reported net income was $5.7B in FY2025, compounding −1.9%/yr from FY2021.

Growth Quality 82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$199B
Latest YoY
+12.6%
Avg. growth/yr (3Y)
+8.3%
Avg. growth/yr (5Y)
+10.3%
Avg. growth/yr (27Y)
+11.3%
Revenue +9.5%/yr
FY21 $139B
FY22 $157B
FY23 $171B
FY24 $177B
FY25 $199B
Net income −1.9%/yr
FY21 $6.1B
FY22 $5.9B
FY23 $6.0B
FY24 $6.0B
FY25 $5.7B

Watch ELV: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Elevance Health, Inc Fair Value". https://www.fairvalue-calculator.com/stock/ELV

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Healthcare Plans · 15 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Top 25%
Fair Value upside +10% · Above median
Return on equity (TTM) 11% · Above median
Return on assets 4% · Above median
Net margin (TTM) 2% · Above median
Operating margin (TTM) 5% · Below median
Revenue growth 1% · Below median
Debt / equity 0.70× · Lower than median

Valuation Multiples vs Healthcare Plans median · lower = cheaper

P/E (TTM) 16.5× · Cheaper than median
P/B 1.84× · Cheaper than median
P/S (TTM) 0.40× · Cheaper than median
P/FCF 25.5× · Pricier than 75% of peers
EV/EBITDA 12.3× · Cheaper than median
PEG 1.43× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 47 · sector 39
FUTURE 7 · sector 23
PAST 45 · sector 41
HEALTH 65 · sector 65
DIVIDEND 35 · sector 0

Insider activity: 46/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $423.38 $292.06 -31%
CVS Health Corporation CVS $104.15 $42.54 -59%
The Cigna Group CI $304.50 $495.42 +63%
Humana Inc HUM $400.00 $127.61 -68%
Centene Corporation CNC $66.61 $111.96 +68%
Molina Healthcare, Inc MOH $233.31 $199.31 -15%
Oscar Health, Inc OSCR $29.10 $58.20 +100%
Alignment Healthcare, Inc ALHC $20.60 $2.37 -88%
Progyny, Inc PGNY $31.93 $16.44 -49%
Bradsaúde S.A SAUD3 R$15.35 R$20.75 +35%

Compare Elevance Health, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Elevance Health, Inc (ELV) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of $431.40 versus a price of $391.40, about +10% (undervalued).
What is the fair value of ELV?
Our model-based fair value for Elevance Health, Inc is $431.40 (as of Jul 17, 2026), built from audited fundamentals. The current price is $391.40.
What is the quality score of ELV?
Elevance Health, Inc has a Quality Score of 65/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of Elevance Health, Inc (ELV)?
Elevance Health, Inc reported trailing-twelve-month revenue of about $200B (latest available figure, as of Jul 17, 2026).
What is the net profit margin of ELV?
The net profit margin of Elevance Health, Inc is about 2.6%, meaning it keeps roughly 2.6% of revenue as net income. Based on the latest reported figures.
Does Elevance Health, Inc pay a dividend?
Elevance Health, Inc currently shows a dividend yield of about 1.76% relative to its recent price (as of Jul 17, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Elevance Health, Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.